BLRX
BioLineRx Ltd.
There isn't enough reported data to score BLRX yet.
BLRX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
BLRX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
BLRX PE Valuation
BLRX has no meaningful PE right now: it lost money over the past year.
BLRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| Low |
Analysts expect BLRX's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
BLRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.00 | +$0.01 |
| Q2 2025 | -$0.01 | +$18.05 |
| Q4 2024 | -$0.01 | +$37.73 |
| Q2 2024 | -$18.06 | +$9.36 |
| Q4 2023 | -$37.74 | -$20.70 |
| Q3 2023 | -$32.40 | -$13.86 |
| Q2 2023 | -$27.42 | -$9.36 |
| Q1 2023 | -$21.48 | -$3.42 |
BLRX is still losing money, but far less than before: $0.00 per share over the past year, against $157.86 at its worst in early 2018.
BLRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $621K | -96% |
| Q2 2025 | $559K | -95% |
| Q4 2024 | $16.7M | +248% |
BLRX's revenue is growing: $621,000 last quarter, down 87% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -901% | -514 points |
| Q2 2025 | -840% | N/A |
| Q4 2024 | -59% | N/A |
| Q2 2024 | -87% | N/A |
| Q4 2023 | -387% | N/A |
BLRX's operating margin was −901% last quarter, down 514 points from the same quarter a year ago, near the bottom of its range since 2023.
BLRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$5.3M | +$13.1M |
| Q2 2025 | -$2.8M | +$22.7M |
| Q4 2024 | -$18.4M | -471% |
| Q2 2024 | -$25.5M | -$15.7M |
| Q4 2023 | $5M | +$10.9M |
| Q3 2023 | -$9.9M | -$1.2M |
| Q2 2023 | -$9.8M | -$3.5M |
| Q1 2023 | -$8.1M | -$2.5M |
BLRX has burned cash in almost every quarter: −$52M over the past year, against −$23M the year before.
BLRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.5% | +171M shares |
| 1 year | +159111% | +2.5B shares |
| 3 years | +208682% | +2.5B shares |
| 5 years | +993157% | +2.5B shares |
| Available history | +1393119% | +2.5B shares |
BLRX has 2.5B diluted shares, up 159111% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
BLRX Net Leverage
BLRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BLRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.5 | Oversold |
| Stochastic | 1.7 | Oversold |
BLRX's weekly RSI is 23 (oversold) and its Stochastic is 2 (oversold).
BLRX PE vs Healthcare Sector
BLRX has no meaningful PE right now: it lost money over the past year.
BLRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.04 | 34% below |
| 20 week MA | $2.49 | 46% below |
| 50 week MA | $2.74 | 51% below |
| 100 week MA | $3.43 | 61% below |
| 200 week MA | $22.8 | 94% below |
BLRX is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
BLRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $91.2 | $103.2 | +13% |
| 2021 | $103.2 | $87.6 | -15% |
| 2022 | $87.6 | $23.2 | -74% |
| 2023 | $23.2 | $62.8 | +171% |
| 2024 | $62.8 | $8.86 | -86% |
| 2025 | $8.86 | $2.90 | -67% |
| 2026 YTD | $2.90 | $1.35 | -53% |
BLRX's yearly returns have swung widely, from +171% in 2023 to −86% in 2024. It's down 53% so far in 2026.